MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, TXG had $129,899K increase in cash & cash equivalents over the period. $130,115K in free cash flow.

Cash Flow Overview

Change in Cash
$129,899K
Free Cash flow
$130,115K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of mark...
    • Stock-based compensation expense
    • Accounts receivable
    • Others
Negative Cash Flow Breakdown
    • Purchase of marketable securitie...
    • Net loss
    • Other receivables
    • Others

Cash Flow
2025-12-31
Net loss
-43,544
Stock-based compensation expense
109,118
Depreciation and amortization
36,199
Asset and lease impairment charges
814
Rou assets impairment due to restructuring
1,253
Amortization of right-of-use assets
7,617
Fair value adjustments on contingent consideration
-1,407
Realized loss on marketable securities
0
Other
-1,753
Accounts receivable
-41,314
Other receivables
34,874
Inventory
-27,953
Prepaid expenses and other current assets
2,343
Other noncurrent assets
-689
Accounts payable
-2,126
Accrued compensation and other related benefits
7,647
Deferred revenue
746
Accrued expenses and other current liabilities
-5,153
Operating lease liability
-10,310
Other noncurrent liabilities
1,396
Net cash provided by (used in) operating activities
136,050
Proceeds from maturities of marketable securities
125,200
Proceeds from sales of marketable securities
0
Purchase of marketable securities
123,435
Asset acquisition, net
9,268
Purchases of property and equipment
5,935
Purchase of intangible assets
0
Net cash (used in) provided by investing activities
-13,438
Issuance of common stock from exercise of stock options and employee stock purchase plan purchases
6,803
Payments on technology license financing arrangement
0
Net cash provided by financing activities
6,803
Effect of exchange rate changes on cash and cash equivalents
484
Net increase (decrease) in cash and cash equivalents
129,899
Cash and cash equivalents at beginning of period
344,067
Cash and cash equivalents at end of period
473,966
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Stock-based compensationexpense$109,118K Accounts receivable-$41,314K Issuance of common stockfrom exercise of...$6,803K Depreciation andamortization$36,199K Inventory-$27,953K Accrued compensationand other related...$7,647K Amortization of right-of-useassets$7,617K Fair valueadjustments on contingent...-$1,407K Other noncurrentliabilities$1,396K Rou assetsimpairment due to...$1,253K Asset and leaseimpairment charges$814K Deferred revenue$746K Other noncurrentassets-$689K Net cash provided by(used in) operating...$136,050K Net cash provided byfinancing activities$6,803K Effect of exchange ratechanges on cash and cash...$484K Canceled cashflow$100,103K Net increase(decrease) in cash and cash...$129,899K Canceled cashflow$13,438K Net loss-$43,544K Other receivables$34,874K Operating lease liability-$10,310K Accrued expenses andother current...-$5,153K Prepaid expenses andother current assets$2,343K Accounts payable-$2,126K Other-$1,753K Proceeds from maturitiesof marketable...$125,200K Net cash (used in)provided by investing...-$13,438K Canceled cashflow$125,200K Purchase of marketablesecurities$123,435K Asset acquisition,net$9,268K Purchases of property andequipment$5,935K

10x Genomics, Inc. (TXG)

10x Genomics, Inc. (TXG)